December 8, 2025Blood

Prophylactic tocilizumab in Relapsed/Refractory multiple myeloma patients treated with bispecific antibodies: A single centre experience

View Full Paper

Ask AI

Bookmark

Authors

VRValeria RuoccoUniversity of Padua TBTamara BernoUniversity of Padua LMLuca MassarottiUniversity of Padua

Discussion

Member takes

Implication

Retrospective analysis reports reduced cytokine release syndrome in patients receiving prophylactic tocilizumab with bispecific antibodies, suggesting improved inpatient management.

Key Points

Prophylactic tocilizumab significantly reduced the incidence of cytokine release syndrome in patients.
Cytokine release syndrome occurred in 46% of patients, primarily grade 1 events after initial doses.
Retrospective evaluation of patients receiving bispecific antibodies between 2023 and 2025 indicated lower rates of adverse events with tocilizumab.
Findings support outpatient treatment feasibility while managing serious adverse events effectively.

Cite This Study

Ruocco et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0b8 https://doi.org/10.1182/blood-2025-7582

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis reports reduced cytokine release syndrome in patients receiving prophylactic tocilizumab with bispecific antibodies, suggesting improved inpatient management.

Prophylactic tocilizumab in Relapsed/Refractory multiple myeloma patients treated with bispecific antibodies: A single centre experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Prophylactic tocilizumab in Relapsed/Refractory multiple myeloma patients treated with bispecific antibodies: A single centre experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider